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Blood-brain barrier–penetrating siRNA nanomedicine 
for Alzheimer’s disease therapy
Yutong Zhou1*, Feiyan Zhu2*, Yang Liu2,3*, Meng Zheng2†, Yibin Wang2, Dongya Zhang2, 
Yasutaka Anraku4, Yan Zou2,5, Jia Li3, Haigang Wu2, Xiaobin Pang3, Wei Tao6, Olga Shimoni7, 
Ashley I. Bush8, Xue Xue1†, Bingyang Shi2,5†
Toxic aggregated amyloid- accumulation is a key pathogenic event in Alzheimer’s disease (AD), which derives 
from amyloid precursor protein (APP) through sequential cleavage by BACE1 (-site APP cleavage enzyme 1) and 
-secretase. Small interfering RNAs (siRNAs) show great promise for AD therapy by specific silencing of BACE1. 
However, lack of effective siRNA brain delivery approaches limits this strategy. Here, we developed a glycosylated 
“triple-interaction” stabilized polymeric siRNA nanomedicine (Gal-NP@siRNA) to target BACE1 in APP/PS1 
transgenic AD mouse model. Gal-NP@siRNA exhibits superior blood stability and can efficiently penetrate the 
blood-brain barrier (BBB) via glycemia-controlled glucose transporter-1 (Glut1)–mediated transport, thereby 
ensuring that siRNAs decrease BACE1 expression and modify relative pathways. Noticeably, Gal-NP@siBACE1 ad-
ministration restored the deterioration of cognitive capacity in AD mice without notable side effects. This “Trojan 
horse” strategy supports the utility of RNA interference therapy in neurodegenerative diseases.
INTRODUCTION
Alzheimer’s disease (AD) is the most common age-related neuro-
degenerative disorder, characterized by progressive deterioration of 
cognitive capacity (1). In 2019, AD affected more than 50 million 
people globally, which is expected to reach 152 million by 2050 (2). 
In addition, the current annual cost of AD worldwide is $1 trillion, 
which is estimated to double by 2030 (2). Currently, clinical therapy 
using acetylcholinesterase inhibitors or N-methyl-d-aspartate receptor 
antagonists are palliative treatment options, which only moderately 
improve cognition and behavior in Alzheimer’s patients but do not 
slow disease progression (3, 4). Hence, it is imperative to develop 
therapeutics targeting pathological mechanisms in AD.
The precise pathological mechanisms leading to AD are not fully 
understood. However, plaques composed of aggregated amyloid- 
peptide (A), neurofibrillary tangles containing hyperphosphorylated 
tau protein, and neuroinflammation are pathological hallmarks (5). 
Among these, the aberrant accumulation of A resulting from the 
sequential cleavage of the amyloid precursor protein (APP) by 
BACE1 (-site APP cleavage enzyme 1) and -secretase activity is 
believed to be a key pathogenic event in AD (6). As a result, strate-
gies that reduce BACE1 activity, and thereby A levels, have been 
considered as a potential therapeutics for AD (7, 8). A skin patch 
consisting of BACE1 inhibitor therapeutics has entered phase 3 
clinical trial (9). However, several BACE1 small-molecule inhibitors 
have been shelved by pharmaceutical companies due to off-target 
toxicity and other safety reasons (10, 11). Despite these recent failures, 
BACE1 is still considered as one of the most promising therapeutic 
targets for AD (8, 11).
Compared to small molecule–based approaches, small interfer-
ing RNAs (siRNAs) offer promising therapeutics for brain disease 
treatment by directly blocking causative gene expression with high 
targeting specificity, low effective doses, and a relatively simple 
drug development process (12). siRNA in a lentiviral vector silenc-
ing BACE1 has also been shown to ameliorate AD neuropathology 
(13). However, effective and safe systemic delivery of siRNA into the 
brain remains challenging, reflecting the presence of biological 
barriers such as the blood-brain barrier (BBB), short circulation 
lifetime, enzymatic degradation, insufficient tissue penetration, cell 
endocytosis, and impaired cytosolic transport. Recent studies have 
shown that nanodelivery approaches hold great potential for over-
coming these challenges (12). It has been reported that the delivery 
of BACE1 siRNA (siBACE1) to the mouse brain by systemic injec-
tion can partially reduce AD neuropathology (14, 15). However, the 
therapeutic efficacy was less than ideal probably due to low siRNA 
brain accumulation and poor stability. In this work, we report an 
effective, nonviral, and BBB-penetrable siBACE1 nanodelivery 
approach that we evaluate in a well-established AD mice model that 
offers the potential for clinical translation.
We developed a glycosylated nanodelivery system, which uses 
glycemia-controlled Glut1 (glucose transporter-1) recycling to facilitate 
nanomedicine BBB penetration for more effective AD therapy (Fig. 1). 
To improve biophysiological protection of the encapsulated siRNA, we 
used a “triple-interaction” stabilization method reported previously (16). 
Specifically, we make use of a guanidinium-phosphate (Gu+/PO34−) salt 
bridge to provide a stabilizing electrostatic and hydrogen bond inter-
action, in addition to the hydrophobic interaction, which is derived 
by the complexation between siRNA and the galactose- modified 
poly(ethylene glycol)-block-poly[(N-(3-methacrylamidopropyl) 
guanidinium [Gal-PEG-b-P(Gu)]/poly(ethylene glycol)- block-poly 
[(N-(3-methacrylamidopropyl) guanidinium-co-2,2,3,3-tetrafluoropropyl 
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methacrylate] [PEG-b-P(GuF)] polymer mixture. Our triple-interaction 
stabilized siRNA nanomedicine demonstrates superior stability per-
formance in blood circulation relative to conventional cationic 
polymer-based nanomedicines that feature only a single electrostatic 
interaction (16). Furthermore, exploiting Glut1 recycling by initially 
inducing hypoglycemia, which elevates Glut1 expression on the 
luminal plasma membrane of the BBB, facilitates markedly enhanced 
delivery of glucose-modified nanocarriers across the BBB when 
Glut1 is recycled to the abluminal membrane of the BBB upon glucose 
replenishment (17–19). To facilitate the Glut1 recycling approach, 
we appreciated that Glut1 stereochemistry allows binding of both 
d-glucose and d-galactose (20–23). We thus hypothesized that our 
galactose-modified siRNA nanomedicines should bind to Glut1 to 
efficiently penetrate the BBB by glycemia-controlled Glut1-mediated 
transport. Consequently, we demonstrate that siBACE1 glycosylated 
siRNA nanomedicine is efficiently delivered to the brains of APP/
PS1 transgenic mice and ameliorates AD-like pathology, leading to 
improvement in cognitive impairment.
RESULTS
Biophysical characterization and in vitro studies  
of Gal-NP@siRNA
In this study, the glycosylated triple-interaction stabilized siRNA 
nanomedicine (Gal-NP@siRNA) was prepared by complexation 
between siRNA and Gal-PEG-b-P(Gu)/PEG-b-P(GuF), which were 
synthesized by reversible addition-fragmentation chain transfer co-
polymerization of hydrophobic monomer 2,2,3,3-tetrafluoropropyl 
methacrylate and siRNA complexation segment N-(3-methacryl-
amidopropyl) guanidinium (Gu) (for detailed synthesis, see scheme S1 
and fig. S1). Because of the hydrophobic interaction of the fluorine 
in P(GuF) for nucleic acid stabilization enhancement (16, 24), gel 
retardation assays demonstrated that the Gal-PEG-b-P(Gu)/PEG-
b-P(GuF) polymer mixture can more effectively encapsulate siRNA 
compared to the fluorine-free Gal-PEG-b-P(Gu) polymers (complete 
siRNA loading weight ratio: 2.5:1 versus 10:1) (Fig. 2A and fig. S2A). 
Moreover, fluorinated nanomedicines showed better performance in 
stability assays compared to fluorine-free counterparts in the negatively 
charged biomacromolecule heparin competition assay (fig. S2B), 
signifying the importance of fluorination to improve the stability of 
siRNA nanomedicines. These siRNA nanoparticles (NPs) were then 
characterized by dynamic light scattering (DLS) and transmission 
electron microscopy (TEM) (Fig. 2, B and C). These results showed 
that Gal-NP@siRNA nanomedicine exhibited a spherical morphology 
with an average size of 118 nm and a low polydispersity index of 
0.13 at a polymer/siRNA mass ratio of 2.5:1. Moreover, the nano-
medicine exhibited excellent stability in both phosphate-buffered 
saline (PBS) and 10% fetal bovine serum (FBS) (fig. S2C).
A key point for siRNA nanodelivery for AD therapy is an effec-
tive neural cell endocytosis and cytosolic transport. Flow cytometry 
analysis and confocal imaging showed that both glycosylated and 
nonglycosylated siRNA nanomedicines are efficiently taken up by 
Neuro-2a cells (Fig. 2, D and E). The Gal-NP@siRNA nanomedicine 
also displayed effective endosome escape ability (fig. S3). In addition, 
competitive cellular binding assay of Gal-NP@Cy5-siRNA in general 
Glut1 inhibitor phloretin treatments showed a dose-dependent uptake 
in Glut1 highly expressed cells (fig. S4), which is consistent with 
previous report (18), indicating Glut1 as the dominant endocytosis 
pathway. Next, to quantify the efficiency of siRNA silencing of the 
target gene, BACE1 mRNA and protein expression were examined 
Fig. 1. Illustration of the formation of the glycosylated “triple-interaction” stabilized siRNA nanomedicine (Gal-NP@siRNA) and the mechanism and approach 
to treat AD pathology in APP/PS1 transgenic mice. (A) Schematic illustration of the fabrication of Gal-NP@siRNA. (B and C) Mechanism by which Gal-NP@siRNA pene-
trates the BBB and accumulates in the brain. Glut1 is overexpressed on the luminal membrane of the BBB after 24-hour fasting. After treatment with Gal-NP@siRNA, glu-
cose replenishment in fasting mice results in Glut1 recycling from the luminal to the abluminal membrane of the BBB, which leads to the transport of Gal-NP@siRNA across 
the BBB. (D) Gal-NP@siRNA–mediated knockdown of BACE1 mRNA expression, which leads to reduced levels of amyloid plaques.
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in Neuro-2a cell samples treated with Gal-NP@siBACE1. The results 
showed that the BACE1 gene was sufficiently silenced in Neuro-2a 
cells (Fig. 2, F and G), achieving approximately 46 and 45% BACE1 
mRNA and protein down-regulation, respectively, while exhibiting 
no obvious toxicity in multiple neuron-related cells (fig. S5). In 
contrast, NPs loaded with scrambled siRNA (siScr) failed to reduce 
BACE1 mRNA and protein levels, corroborating the sequence- 
specific gene silencing activity of siBACE1. The superior silencing 
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Fig. 2. Biophysical characterization and in vitro studies of Gal-NP@siRNA. (A) Gel retardation assay of Gal-NP@siRNA at polymer/siRNA weight ratios of 1, 2.5, 5, 10, 
15, and 20. (B) Size distribution and (C) transmission electron micrographs of Gal-NP@siRNA. (D) Confocal laser scanning microscopy images for NP cellular uptake. Images 
were collected for Neuro-2a cells after 4-hour NP incubation. Cell nuclei were stained with DAPI (blue), siRNA was labeled by FAM dye (green), and cell cytoskeleton was 
stained with TRITC-phalloidin (red) to indicate cytoplasm area. Scale bars, 10 m. (E) Flow cytometry analysis of Neuro-2a cells following 4-hour incubation with free 
Cy5-siRNA, NP@Cy5-siRNA, and Gal-NP@Cy5-siRNA. (F and G) In vitro gene silencing effects of Gal-NP@siBACE1 and controls at day 3 post transfection. BACE1 mRNA (F) 
and protein (G) expression levels was quantified by qRT-PCR and western blot assay, respectively. Data are presented as mean ± SEM (n = 3, ***P < 0.001). 
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ability of Gal-NP@siBACE1 in Neuro-2a cells likely reflects their 
stable encapsulation and siRNA protection, efficient cellular inter-
nalization, and endosome escape, characteristics that show promis-
ing potential for in vivo study.
Biodistribution and in vivo BACE1 targeting efficacy  
of Gal-NP@siRNA
Next, to evaluate in vivo pharmacokinetics, the plasma levels of 
Cy5-labeled siRNA were measured after intravenous injection of 
free siRNA, fluorinated siRNA nanomedicine, and fluorine-free siRNA 
nanomedicines. These data demonstrated that the fluorinated siRNA 
nanomedicine (Gal-NP@siRNA) had the longest blood circulation 
time with an elimination half-lifetime (t1/2) of 39.2 min (Fig. 3A), 
which was significantly longer than that of both the fluorine-free 
counterpart and free siRNA (t1/2 of 22.0 and 8.0 min, respectively; 
fig. S6A and Fig. 3A). These circulation results were consistent with 
the data above demonstrating biophysical stability and good hepa-
rin competition characteristics, further confirming the excellent 
stability of fluorinated siRNA NPs. Subsequently, we studied the 
in vivo brain targeting of our glycosylated siRNA nanomedicine by 
glycemia-controlled Glut1-mediated transport. The biodistribution 
of Gal-NP@Cy5-siRNA was quantified by fluorometry. These ex-
periments demonstrated that the brain accumulation of Gal-NP@
Cy5-siRNA nanomedicine was up to 5.8-fold higher than that of 
non–galactose-modified NP@Cy5-siRNA nanocarriers (Fig. 3B and 
fig. S6B). In addition, we also observed that the siRNA brain accu-
mulation reached a peak at 1 hour after injection and maintained a 
considerable fluorescence accumulation up to 24 hours, as monitored 
by Cy5 in vivo imaging (Fig. 3C), and the BACE1 mRNA and protein 
expression in cortex was inhibited after nanomedicine treatment 
(Fig. 3, D and E, and fig. S6C).
Behavioral evaluation of Gal-NP@siBACE1 nanomedicine 
therapy in APP/PS1 mice
To evaluate the therapeutic effect of Gal-NP@siBACE1 in a relevant 
AD pathology model, the APP/PS1 double transgenic mouse model 
was assessed in behavioral tests of learning and memory impair-
ment relevant to AD. The APP/PS1 double transgenic mouse is a 
commonly used multitransgenic animal model that expresses two 
familial AD mutant genes for APP together with mutant presenilin 
1 (PS1). Compared to single transgenic mice and other nongenetic 
AD mouse models, APP/PS1 mice express accelerated amyloid 
deposition and synaptic loss with reliable memory deficits (25–27). 
BACE1 inhibition has been reported to prevent neuron loss and 
memory deficits in APP/PS1 mice (28), demonstrating suitability for 
evaluating the therapeutic efficacy of novel nanocarriers in this model.
To determine whether Gal-NP@siBACE1 nanomedicine could 
ameliorate neuropathology in APP/PS1 transgenic mice, APP/PS1 
mice were given Gal-NP@siBACE1 or control Gal-NP@siScr (siRNA, 
1 mg/kg) via caudal vein injection every 3 days (Fig. 4A). The same 
dose of non–galactose-modified NP@siBACE1 was assessed as a 
negative control. PBS-injected APP/PS1 and control wild-type (WT) 
mice groups were included to ascertain AD-relevant deficits in 
APP/PS1 mice at baseline. Behavioral tests including the novel 
object recognition (NOR) test and the Morris water maze (MWM) 
were performed to examine spatial learning and memory, while the 
nest-building test was used to assess general health and hippocampal 
function, because nest building is often impaired in rodent models 
of AD (29–32).
Experimental nesting data showed that Gal-NP@siBACE1–
treated APP/PS1 mice achieved a similar score to WT mice, 
which was much better than all other APP/PS1 control groups 
(Fig. 4, B and C). Furthermore, the NOR test results showed that 
PBS-treated APP/PS1 control mice showed suppressed interest in 
exploring novel objects compared with WT mice as determined by 
discrimination index (DI) and preference index (PI) for novel 
object (Fig. 4, D to F). After being treated with Gal-NP@siBACE1, 
APP/PS1 mice showed a significant increase in NOR compared 
to PBS-treated APP/PS1 control mice. Excitingly, the DI and PI 
for novel object reached the performance of normal WT mice 
(Fig. 4, E and F). In contrast, control APP/PS1 mice treated with 
non–galactose-modified NP@siBACE1 or Gal-NP@siScr performed 
as poorly as PBS-treated control APP/PS1 mice, signifying the 
importance of the targeting ability of the galactose ligand and the 
therapeutic effect of siBACE1 brain delivery. In the MWM test, all 
groups achieved comparable escape latencies (fig. S7) during the 
five training days.
On the probe test day, when the escape platform was removed, 
long-term spatial memory has been investigated (Fig. 4, G to J). How-
ever, on probe test day, mice administered with PBS, NP@siBACE1, 
and Gal-NP@siScr showed an aimless searching strategy with no or 
only slightly improved spatial learning and memory (see representa-
tive tracking plots in Fig.  4G), with reduced time in the target 
quadrant but similar swimming speed compared to WT controls 
(Fig. 4, H and I). In contrast, APP/PS1 mice treated with Gal-NP@
siBACE1 exhibited a greater proportion of time in the target 
quadrant and number of platform crossings compared to PBS- 
injected controls (Fig. 4, I and J). These data confirm that the 
Gal-NP@siBACE1 nanomedicine mediates highly effective siRNA 
brain delivery to significantly improve cognitive performance in 
APP/PS1 mice.
Effects of the Gal-NP@siBACE1 treatment on APP processing 
and amyloid deposition in APP/PS1 mice
After behavioral tests were completed, mice were sacrificed, and 
brain tissue was collected for analysis of BACE1 suppression and its 
impact on A and tau pathological accumulation (Fig. 5A). Our 
results showed that both hippocampal and cortical BACE1 protein 
levels in Gal-NP@siBACE1–treated APP/PS1 mice were significantly 
decreased compared to other APP/PS1 control groups (Fig. 5B and 
fig. S8, A and B), in agreement with the improvement in behavioral 
tests. Hence, effective BACE1 protein silencing shown by Gal-NP@
siBACE1 demonstrates a reliable siRNA delivery approach for 
targeting the brain. The manifestation of pathological hallmark 
of AD, amyloid plaques derived from BACE1-cleaved APP, was 
significantly decreased with reduced foci size in both the hippo-
campus and cortex of Gal-NP@siBACE1–treated APP/PS1 mice 
(Fig. 5, C and D). In sharp contrast, control PBS–, NP@siBACE1-, 
or Gal-NP@siScr–treated mice exhibited pronounced A plaque 
deposition (Fig. 5, C and D). Another major pathological feature 
of late-stage AD is the development of intracellular neurofibrillary 
tangles composed of hyperphosphorylated tau protein (p-tau), 
which synergistically impairs cognitive performance in AD patients 
(33). Our data showed that both hippocampal and cortical p-tau 
levels in AD mice treated with Gal-NP@siBACE1 were lower than 
those in control AD mice treated with PBS (Fig. 5E and fig. S8C), 
probably attributable to the molecular interplay between A and 
p-tau (34, 35).
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BACE1 deficiency can impair remyelination, which negatively 
affects cognitive function (36). Therefore, it is imperative to knock 
down BACE1 to an appropriate therapeutic level. To check this, we 
followed the expression of the multilamellar myelin sheath for-
mation marker myelin basic protein (MBP) in the central nervous 
system (CNS). In PBS-treated control APP/PS1 mice, the expres-
sion of MBP in the brain was significantly decreased (Fig. 5F and 
fig. S8D), indicating the negative consequences of A deposition on 
myelin, which was consistent with reported literature (37). In con-
trast, MBP protein expression was restored in AD mice treated 
with Gal-NP@siBACE1 to levels seen in WT mice (Fig. 5F), thereby 
indicating that the dose of siBACE1 was appropriate and sufficient 
to neutralize A toxicity.
Cytotoxicity and in vivo biocompatibility assessment 
of the Gal-NP@siRNA nanomedicine
To further assess the biocompatibility and systemic response to the 
nanomedicine, we assessed routine blood parameters and chemistry 
by measuring plasma alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), plasma urea 
(BUN), uric acid (UA), creatinine (CR), as well as blood platelet 
(PLT), red blood cells (RBCs), and white blood cells (WBCs) 
(Fig. 6, A and B, and fig. S9A). To evaluate the inflammatory concern 
of the nanomedicine treatments, core proinflammatory cytokines 
such as Il-1, Il-6, and Tnf- have been tested in liver and kidney 
(Fig. 6, C and D). These examinations demonstrated no significant 
difference between PBS and Gal-NP@siRNA treatment groups 
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Fig. 3. Biodistribution and in vivo BACE1 targeting efficacy of Gal-NP@siRNA. (A) In vivo pharmacokinetics as shown by Cy5-siRNA concentration/time curves in 
plasma after a single-dose injection. (B) (Left) Quantification of Cy5-siRNA accumulation in different organs. Cy5-siRNA levels were determined by fluorescence spectros-
copy 1 hour after tail vein injection of siRNA nanomedicine after a single-dose injection. Data are presented as mean ± SEM (n = 3, *P < 0.05). (Right) Representative image 
for Cy5 signal in the brain of NP@siRNA and Gal-NP@siRNA groups 1 hour after injection. (C) Time course in vivo imaging of Gal-NP@Cy5-siRNA evaluated by fluorescence 
imaging after a single-dose injection. (D and E) BACE1 mRNA and protein expression level in cortex was quantified by (D) qRT-PCR and (E) Western blot assay from WT 
mice samples, and samples were collected at day 3 after two nanomedicine treatments. Data are presented as mean ± SEM (n = 3, *P < 0.05).
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Fig. 4. Behavioral evaluation of Gal-NP@siBACE1 nanomedicine therapy in APP/PS1 mice. (A) Schematic of the experimental timeline. APP/PS1 and WT mice were 
treated with siRNA nanomedicine or PBS via tail vein injection every 3 days (10 cycles). Mice were then subjected to nesting, NOR, and MWM tests for memory evaluation, 
and samples for molecular pathological assessments were collected. (B) Representative images and scoring criteria from the nest-building experiment in APP/PS1 and 
control WT mice. Photos were taken 24 hours after the introduction of nesting material to the home cage. Photo credits: Yutong Zhou, Nankai University. (C) Nest-building 
scores for each group. (D) Setup for NOR test. (E and F) Results for NOR test. (E) DI and (F) PI of each group after nanomedicine treatment. (G to J) Data for probe test in 
the MWM. (G) Representative swimming track, (H) swimming speed, (I) ratio of time spent in target quadrant, and (J) number of crossing the platform location of each 
group on the probe test day. All behavioral test bar or plot charts are presented as mean ± SEM (n = 6 to 8, *P < 0.05, **P < 0.01).
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Fig. 5. Therapeutic evaluation of the ability of Gal-NP@siBACE1 treatment to modulate AD hallmarks in APP/PS1 mice. (A) Mechanistic explanation for the effects 
of siBACE1 therapy. (B) Representative Western blot data for BACE1 protein expression in hippocampus and cortex from nanocarrier-treated APP/PS1 mice, control APP/
PS1 groups, and WT mice. Quantification of Western blotting analysis of BACE1 expression was relative to -actin (n = 3, mean with SEM, *P < 0.05, **P < 0.01). (C) Representa-
tive confocal laser scanning microscopy imaging data assessing amyloid plaque burden. Immunofluorescence of A plaques (green) in hippocampus and cortex from 
APP/PS1 transgenic and WT mice. Nuclei were stained by DAPI (blue). Scale bars, 100 m. (D) Percent surface area of amyloid plaques in hippocampus (left) and cortex 
(right) regions was quantified. Data are presented as mean ± SEM; n = 4, **P < 0.01. (E) p-tau and (F) MBP expression in the hippocampus and cortex for nanocarrier-treated 
APP/PS1 mice, control APP/PS1 groups, and WT mice (top). Quantification of Western blotting analysis was relative to -actin (bottom) (n = 3, mean with SEM, *P < 0.05, 
**P < 0.01). All samples were collected after 10 administrations of nanomedicine.
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Fig. 6. Cytotoxicity and in vivo biocompatibility assessment of the Gal-NP@siRNA nanomedicine. (A and B) Blood chemistry examinations. Assessment of plasma 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), plasma urea (BUN), creatinine (CR), and uric acid (UA) levels after a 
single-dose nanomedicine treatment. n = 4, mean with SEM. (C and D) Core proinflammatory cytokines such as Il-1, Il-6, and Tnf- in liver (C) and kidney (D) were assessed 
after a single-dose PBS or Gal-NP@siRNA nanomedicine treatment at days 2 and 14. n = 3, mean with SEM. (E) Representative data for hematoxylin and eosin staining in 
major organs from APP/PS1 and control WT mice treated with Gal-NP@siBACE1 or PBS in the 10-time injection therapeutic experiments. Scale bars, 50 m.
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within 2 weeks after injection, indicating that the Gal-NP@siRNA 
nanomedicine has a suitable safety profile and can survive free 
circulation in blood before its arrival at the target site in the brain. 
In addition, during nanomedicine therapy, there were no differences 
between treatment groups in body weight change or food uptake, 
further indicating the safety of the glycemia-controlled strategy for 
Gal-NP@siBACE1 nanocarriers (fig. S9B). Histochemical staining 
showed that treatment with Gal-NP@siBACE1 nanocarriers induced 
no necrosis or apoptosis in major organs (Fig. 6E) after 10 cycles of 
nanomedicine treatment.
DISCUSSION
Integration of RNAi together with nanotechnology holds great 
promise for AD therapy. However, nanotechnology-based therapy 
has been put off by stringent regulatory framework (12, 38). Clinical 
translation of nanomedicines is often hindered by multiple factors, 
including physical and chemical stability of nanomedicine, pharma-
cokinetic parameters, in vivo release mechanism, the robustness of 
manufacturing, route of administration, bioavailability, distribu-
tion, biodegradation, safety, accumulation, and appropriate animal 
studies (39, 40). Most published studies examining nanomedicines 
as potential AD therapeutics address a limited number of these 
factors, which probably explains why these have largely been unsatis-
factory in terms of efficacy and efficiency. In the work of Singer et al. 
(13), a siBACE1 lentiviral vector was applied by intracerebral injec-
tions. This early proof-of-concept study showed considerable potential 
in BACE1 silencing strategy. However, several critical limitations 
including toxicity, immunogenicity, and inflammatory response 
hinder the therapeutic use of the lentiviral vector in CNS disease 
(41). Also, intracerebral injection of the siRNA is destructive and 
may cause multiple side effects. Exosomes hold excellent capacity 
for reduce immunogenicity and siBACE1 brain delivery (14). How-
ever, preparing enough quantity of purified exosomes remains 
challenging when this concept moves to clinics. Polymeric NPs are 
easier to synthesize and scale up and also display low immunogenicity. 
A pioneering study developed synthesized polymeric nanoplatforms 
that deliver siRNAs to AD mice brain, but poor in vivo stability and 
ineffective brain accumulation limit its therapeutic effect (15). Still, 
more powerful nanomaterials are urgently needed to overcome current 
poor blood stability and inefficient BBB penetration (42). Here, we 
developed a self-assembly method based on galactose-decorated 
triple-interaction stabilized polymeric siRNA nanomedicine 
(Gal-NP@siRNA). Our nanomedicine formulation produces siRNA- 
loaded NPs through simple mixing of prepared polymers with the 
required siRNA sequence in a tunable ratio manner. The simplicity 
and versatility of our nanomedicine formulation can support assembly 
of NPs loaded with any short nucleic acids. We demonstrate that 
our nanomedicine formulation has superior physiological stability 
and blood longevity that is critical for siRNA to achieve high accumu-
lation at diseased sites. To date, most reported siRNA nanomedicines 
were solely electrostatically stabilized, which makes them susceptible 
to dissociation in vivo, leading to short circulation time in blood. In 
this study, the combination of Gu+/PO34− salt bridge that promotes 
additional electrostatic and hydrogen bond interaction with the 
fluorine-mediated hydrophobic interaction overcomes the stabili-
zation problem of typical siRNA nanomedicines and further endows 
Gal-NP@siRNA with superior physiological stability and prolonged 
blood circulation time.
In addition to the stability challenge, effective BBB penetration 
is another big challenge for nanotechnology-based brain disease 
therapies. By design, our Gal-NP@siRNA–incorporated d-galactose 
makes it possible to exploit glycemic Glut1 recycling, enhancing the 
delivery of Gal-NP@siRNA across the BBB upon glucose adminis-
tration. Potentially, this BBB-penetrating strategy is feasible clinically, 
as blood glucose spikes are easily induced through oral (glucose 
drink) or intravenous administration. Glut1 transporter expression 
and nutrition uptake decrease with age in AD patients (43, 44). 
From this aspect, it may have an impact on the therapeutic efficiency 
of Gal-NP@siRNA to some extent, especially in a senior AD model. 
Another controversial point is that researchers found that BBB per-
meability increased in AD, which contributes to cognitive decline 
independently of AD pathology (45, 46). However, the ineffective 
AD therapeutic ability of nontargeted NP@siRNA signifies the 
importance of Glut1-mediated transport for galactose-modified 
nanomedicines crossing the BBB.
In addition to excellent blood stability and effective BBB pene-
tration, we also show that Gal-NP@siRNA nanomedicine exerts 
high brain accumulation. Gal-NP@siBACE1 decreased BACE1 
expression, leading to reduced levels of A plaques with the added 
benefit of suppressed phosphorylated tau protein levels and regener-
ation of impaired myelin. These positive pathophysiological effects 
probably contributed to the restoration of cognitive performance of 
Gal-NP@siBACE1–treated transgenic mice. In addition, Gal-NP@
siRNA also exhibited excellent biocompatibility and did not cause 
renal or hepatic responses or adverse effects on myelination, sug-
gesting that there is an effective clearance of by-products from the 
brain most likely via the paravascular glymphatic pathway (47).
AD is a complex neurodegenerative disorder, and the pathological 
pathways that govern AD are still controversial. Nonetheless, the 
toxic A accumulation and tauopathy are two of the most reliable 
pathologic events in AD progression. In several early studies, inhi-
bition of BACE1 mRNA levels lowers -secretase activity associated 
with BACE1 and consequently reduces production of APPs and 
other proteins in cells (48–50). Therefore, BACE1 is considered one 
of the top drug targets for lowering cerebral A plaque levels in AD.
We demonstrated partial knockdown of BACE1 protein expres-
sion, but there are several variants of that protein, and in subsequent 
studies, our Gal-NP@siRNA could be applied to carry multiple siRNAs 
for holistic therapy. In addition, our therapeutic approach is suit-
able for “gene therapy cocktail” applications.
In summary, we developed an effective strategy to deliver siBACE1 
through the BBB with good circulation stability, which ameliorated 
AD-like pathology in APP/PS1 transgenic mice. These results indicate 
that our Gal-NP@siRNA nanomedicine has good clinical translation 
potential for AD therapy owing to ease of formulation, stability, and 
BBB penetration. Furthermore, our Gal-NPs could also be used to 
deliver siRNA in a wide range of CNS disease therapy including 
other neurodegenerative conditions and brain cancer.
MATERIALS AND METHODS
Materials
See the Supplementary Materials for the synthesis of MeO-PEG-b-
P(GuF) and Gal-PEG-b-P(Gu). Primary antibody BACE1 (Abcam, 
AB183612), p-tau (Abcam, AB151559), MBP (Abcam, AB40390), 
-actin (Abcam, AB8226), or glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (Abcam, AB181602) and mouse or rabbit secondary 
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antibody (LI-COR IRDye 800CW) were used. All siRNAs were syn-
thesized by GenePharma Company, and the sequences used were as 
follows: (i) Scramble: 5′-UUCUCCGAACGUGUCACGUdTdT-3′ 
(sense) and 5′-ACGUGACACGUUCGGAGAAdTdT-3′ (antisense); 
(ii) BACE1: 5′-GAACCUAUGCGAUGCGAAUdTdT-3′ (sense) and 
5′-AUUCGCAUCGCAUAGGUUCdTdT-3′ (antisense). The siBACE1 
sequence was shown in a previous work, which showed a better 
silencing effect among several sequences (51). A dye was introduced 
to the 5′-end of the antisense strand of siScr. For quantitative poly-
merase chain reaction (qPCR), all of these primers are designed by 
Primer-BLAST (National Center for Biotechnology Information) and 
listed in table S1.
Nanocarrier characterization
1H nuclear magnetic resonance spectra were recorded on AVANCE 
III HD 400 MHz (Bruker, Switzerland). The size was determined at 
25°C using DLS (Zetasizer Nano-ZS, Malvern Instruments) equipped 
with a 633-nm He-Ne laser using backscattering detection. TEM 
was performed using a JEM-2100 TEM operated at an accelerating 
voltage of 200 kV (JEOL, Japan). The confocal laser scanning micros-
copy images of cells were taken on a Zeiss Confocal Microscope 
system (Zeiss 880). The transfected cells were observed with a 
microplate reader (Molecular Devices, USA), and fluorescence was 
quantitatively measured by flow cytometry (BD FACSCalibur, 
San Jose). The gel electrophoresis images were taken by Molecular 
Imager FX (Bio-Rad, Hercules, CA). The fluorescent images were 
scanned using a near-infrared fluorescence imaging system (Lumina, 
IVIS III).
Gel retardation assay
siRNA (0.5 mg) was dissolved in 500 l of diethyl pyrocarbonate–
treated water. Polymer and siRNA solutions were mixed (the amount 
of siRNA was 2 M) at polymer/siRNA weight ratios of 1:1, 2.5:1, 
5:1, 10:1, 15:1, and 20:1. The mixture was incubated for 30 min. The 
siRNA binding ability of polymer was studied by agarose gel. The 
polymer/siRNA ratios were electrophoresed through a 2% agarose 
gel containing Gel Red at 35 V in TAE solution [40 mM tris-HCl, 
1% acetic acid (v/v), and 1 mM EDTA]. Fluorine-free Gal-NP 
(mixed with siRNA at a mass ratio of 10:1) and fluorinated Gal-NP 
(mixed with siRNA at a mass ratio of 2.5:1) were prepared, and 
then different doses of heparin solution were added to the NPs. 
siRNA release was measured by a nucleic acid gel at different 
time points.
siRNA nanomedicine formulation
The siRNAs were dissolved in Hepes buffer (pH 7.4) to a stock con-
centration of 4000 nM (53.2 g/ml) for in vitro experiments and 
400 g/ml for animal experiments. The polymer solution was added 
into the siRNA solution (volume ratio = 1:1) and then gently pipetted 
10 times and incubated for 30 min at room temperature. Then, the 
prepared nanomedicines were diluted into a working concentration 
of 200 or 400 nM siRNA for in vitro experiments and 200 g/ml for 
in vivo experiments. Gal-PEG-b-P(Gu) and MeO-PEG-b-P(Gu)/
MeO-PEG-b-P(GuF) (molar ratio = 1:3) complexed with siRNA 
yielded nanomedicine denoted as fluorine-free Gal-NP@siRNA 
(polymer/siRNA weight ratio = 10) and NP@siRNA (polymer/
siRNA weight ratio = 2.5:1). Gal-PEG-b-P(Gu)/MeO-PEG-b-P(GuF) 
(molar ratio = 1:3) complexed with siRNA yielded Gal-NP@siRNA 
nanomedicine (polymer/siRNA weight ratio = 2.5:1).
Flow cytometry assay
Neuro-2a cells were seeded in a six-well plate (1 × 106 cells per well) 
and incubated with PBS, Gal-NP@Cy5 siRNA, NP@Cy5-siRNA, 
and naked Cy5-siRNA in 500-l medium (200 nM Cy5-siRNA) at 
37°C for 4 hours. The cells were digested by 0.25% (w/v) trypsin and 
0.03% (w/v) EDTA. The suspensions were centrifuged at 1000 rpm 
for 3 min, washed twice with PBS, and then resuspended in 500 l 
of PBS. Fluorescence histograms were immediately recorded with a 
BD FACSCalibur flow cytometer (Becton Dickinson, USA) and 
analyzed using CellQuest software based on 10,000 gated events. 
The gate was arbitrarily set for the detection of Cy5 fluorescence.
In vitro cytotoxicity assay
Neuro-2a, SH-SY5Y, and PC-12 cells were seeded in 96-well plates 
(6000 cells per well) and incubated in 100 l of culture medium for 
24 hours. Thereafter, PBS, NP@siRNA, Gal-NP@siRNA, and naked 
siRNA NPs were added to the cells, and the cells were then incubated 
for 48 hours. At assay end, 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- 
phenytetrazoliumromide (MTT) solution (5 mg/ml, 1 l/10 l of 
medium) was added and samples were further incubated at 37°C for 
4 hours. Cell viability was determined from the absorbance of extra-
cellular medium at 570 nm.
Gene silencing assay by quantitative real-time PCR
Endogenous BACE1 gene silencing activity of Gal-NP@siRNA was 
investigated by quantitative real-time PCR (qRT-PCR). Neuro-2a 
cells were seeded in a six-well plate (1 × 106 cells per well) in growth 
medium (Minimum Essential Medium/Earle’s Balanced Salt Solu-
tion also known for MEM/EBSS containing 10% FBS) for 24 hours. 
The medium was removed and replenished with fresh medium 
(1000 l) containing PBS, NP@siScr, NP@siBACE1, Gal-NP@siScr, 
and Gal-NP@siBACE1 (400 nM siRNA). After 3 days, the cells were 
washed with PBS and the total RNA was extracted using the RNeasy 
Mini Kit (Qiagen).
For mice experiments, normal female Balb/c mice were randomly 
divided into two treatment groups (n = 3). PBS and Gal-NP@siScr 
(1 mg of siRNA equiv./kg) were intravenously injected into mice via 
the tail vein (n = 3 per group). At prescribed time points after injec-
tion, animals were anesthetized and transcardially perfused with 
saline. The tissues were homogenized in 1 ml of ice-cold TRIzol 
reagent (Invitrogen) according to the protocol of the manufacturer. 
Reverse transcription and qPCR were carried out by following 
reverse transcription protocol (Takara) and SYBR Green Gene Ex-
pression Assays Protocol (Takara) with the Roche LightCycler 480 
RT-PCR System. mGAPDH was used as an endogenous house-
keeping gene to normalize the Bace1 mRNA. The mRNA expres-
sion level was calculated based on comparative Ct method (2−∆∆Ct).
Animals
All animals used for experiments were allocated blindly to treatment 
groups. All protocols were approved by the Animal Care and Use 
Committee of Laboratory Animal Center, Henan University (ethics 
approval number: HUSOM-2018-354). Adult, 8-week female Balb/c 
mice were used in the biodistribution assay, in vivo BACE1 silenc-
ing, and blood biochemistry examinations. For in vivo imaging 
experiments, 8-week female nude mice were used. For therapeutic 
evaluation experiments and animal behavior tests, 8-month male 
APP/PS1 and C57BL/6 mice (WT-like littermates) were used. All 
mice were provided by Beijing Vital River Laboratory Animal 
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Technology Co. Ltd. and transported to the animal facility at Nankai 
University or Henan University at least 2 weeks before testing. Mice 
were housed in a standard individual ventilation cages animal exper-
imental system (Suzhou Fengshi Laboratory Animal Equipment Co. 
Ltd.) with corn cob bedding and a wire lid, providing climbing oppor-
tunities (APP/PS1 and its control mice were housed one mouse per cage 
for experiments). Mice were kept under a 12:12-hour day-night 
schedule; food and water were available ad libitum. Separate cohorts 
were used for each experiment (n = 6 to 8 per treatment group, WT-
PBS = 8, AD-PBS = 7, AD-NP@siBACE1 = 6, AD-Gal-NP@siScr = 6, 
AD-Gal-NP@siBACE1 = 7). Food was removed for fasting 24 hours 
before nanomedicine treatment. Two hundred microliters of 20 weight 
% (wt %) glucose was administered to all groups by intraperitoneal 
injection 30 min before nanomedicine injection. For nanomedicine 
treatment, we administered NPs modified with or without galactose 
(Gal-NP@siBACE1 or NP@siBACE1) to verify Glut1 targeting 
and effective brain delivery. Gal-NPs loaded with siBACE1 or siScr 
(Gal-NP@siBACE1 or Gal-NP@siScr) were designed to assess 
gene silencing efficiency. APP/PS1 and WT-like mice injected with 
200 l of PBS were used as controls to demonstrate pathological 
dysfunction in AD mice. All AD nanomedicine therapy groups 
were given 1 mg of siRNA equiv./kg diluted in 200 l of PBS via 
caudal vein injection every 3 days. Treatment schedules for injec-
tion of siRNA nanomedicines and behavior test date are highlighted 
in Fig. 4A.
Pharmacokinetics
Gal-NP@Cy5-siRNA, fluorine-free Gal-NP@Cy5-siRNA, and naked 
Cy5-siRNA (1 mg of Cy5-siRNA equiv./kg) in 200 l of Hepes were 
intravenously injected into mice via the tail vein (n = 3). At pre-
scribed time points after injection, ~50 l of blood was taken out 
from the eye socket of mice. The blood samples were immediately 
dissolved in 0.6 ml of lysis buffer (1% Triton X-100) at 37°C over-
night followed by centrifugation (14,000 rpm, 30 min). The Cy5 
level in the supernatant was determined by fluorometry. The blood 
circulation followed a typical two-compartment model: a rapid de-
cline in the distribution phase and a long period in the elimination 
phase. We calculated the half-lives of two phases (t1/2, and t1/2,) by 
fitting the experimental data using SoftwareS6 Origin 8 exponential 
decay 2 model: y = A1 × exp(−x/t1) + A2 × exp(−x/t2) + y0, and then 
taking t1/2, = 0.693 × t1 and t1/2, = 0.693 × t2.
Biodistribution
After fasting (1 day), glucose solution (20 wt %) was injected to elevate 
the blood glucose concentration, and 30 min later, a single dose of 
NP@Cy5-siRNA and Gal-NP@Cy5-siRNA in 200 l of Hepes was 
administrated intravenously via the tail vein (1 mg of siRNA equiv./kg). 
After 1 hour, the mice were sacrificed. The major organs including 
heart, liver, spleen, lung, kidney, and brain were collected, washed, 
dried, weighed, and homogenized in 0.6 ml of 1% Triton X-100 with 
a homogenizer at 14,000 rpm for 30 min. Cy5 in the supernatant 
was determined by fluorometry based on a calibration curve and 
expressed as injected dose per gram of tissue (%ID/g).
In vivo and ex vivo imaging
To evaluate the in vivo brain targeting ability of NPs, Gal-NP@
Cy5-siRNA and NP@Cy5-siRNA were injected intravenously to 
nude mice and monitored at different time points by using the Lumina 
IVIS III Imaging System (excitation = 620 nm; emission = 670 nm).
To evaluate the ex vivo brain targeting and NP biodistribution, 
Gal-NP@Cy5-siRNA and NP@Cy5-siRNA were injected intravenously 
to nude mice after fasting. One hour after injection, main organs 
were separated, washed in PBS, and monitored.
Western blot
Neuro-2a cells were harvested at day 3 after incubation with Gal-
NP@Cy5-siRNA and control vectors. For sufficient siBACE1 verifi-
cation, mouse brain tissues were taken from Balb/c mice after two 
siRNA injections. In therapeutic evaluation, mouse brain tissues were 
taken 1 day after completion of behavioral assessments. Animals 
were anesthetized and transcardially perfused with saline. Tissue 
(whole hippocampus and cortex) and cells were homogenized in 
radioimmunoprecipitation assay lysis buffer with a proteinase and 
phosphorylase inhibitor cocktail (Thermo Fisher Scientific) and 
centrifuged for 15 min (12,000 rpm, 4°C). The protein concentra-
tion of the supernatant was determined using the BCA Protein 
Assay Kit (Beyotime, China). Standard Western blot electrophoresis 
was then performed, with proteins transferred onto polyvinylidene 
difluoride membranes (Millipore 0.22 m) and immunoblotted. 
Primary antibody BACE1 (Abcam, AB183612), p-tau (Abcam, 
AB151559), MBP (Abcam, AB40390), -actin (Abcam, AB8226), or 
GAPDH (Abcam, AB181602) and mouse or rabbit secondary anti-
body (LI-COR IRDye 800CW) were used. Data quantification was 
performed by ImageJ software.
Confocal microscopy imaging
For cellular uptake assay, Neuro-2a cells were cultured on micro-
scope slides in 24-well plates (1 × 105 cells per well) and incubated 
with NP@FAM-siRNA, Gal-NP@FAM-siRNA, or naked FAM-siRNA 
in 500 l of medium (200 nM FAM-siRNA) at 37°C. The culture 
medium was removed, and the cells were washed three times with 
PBS, fixed with 4% paraformaldehyde solution for 15 min, and 
washed three times with PBS. Cells were then permeabilized with 
0.1% Triton X-100 in PBS for 15 min and then stained with a tetra-
methyl rhodamine isothiocyanate (TRITC) fluorescent phalloidin 
conjugate solution (10 g/ml) in PBS (containing 1% dimethyl sulf-
oxide from the original stock solution) for 30 min at room tempera-
ture and washed three times with PBS. The cell nuclei were stained 
with 4′,6-diamidino-2-phenylindole (DAPI) for 10 min and washed 
three times with PBS. The fluorescence images were obtained using 
a confocal microscope (Zeiss 880).
For endosomal escape, Neuro-2a cells were cultured on micro-
scope slides in 24-well plates (1 × 105 cells per well) and incubated 
with Gal-NP@FAM-siRNA in 500 l of medium (200 nM FAM-siRNA) 
at 37°C for 2, 4, 6, and 8 hours. At the determined time, the culture 
medium was removed and the cells were washed three times with 
PBS and incubated with LysoTracker (50 nM, Invitrogen) at 37°C 
for 30 min and then with Hoechst 33342 (Solarbio, 10 g/ml) for 
10 min to visualize the endosomes/lysosomes and nuclei. Thereafter, 
cells were washed three times with PBS and fixed with 4% para-
formaldehyde solution for 15 min. Fluorescence images were obtained 
using a confocal microscope (Zeiss 880).
For tissue immunofluorescence, brains were fixed in 4% para-
formaldehyde for 24 hours, then dehydrated, embedded, and cut 
into 8-m frozen slices. The sections were washed three times with 
PBS, blocked with normal goat serum for 1 hour, and subsequently 
incubated with anti–-amyloid primary antibody (1:200, BioLegend, 
catalog no.803001) or anti-BACE1 primary antibody (1:250, Abcam, 
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AB183612) overnight at 4°C. Sections were then washed three times 
with PBS, and the slices were incubated with fluorescein isothiocyanate 
(FITC)–conjugated goat anti-mouse immunoglobulin G (IgG) 
(1:200, Abcam) or FITC-conjugated goat anti-rabbit IgG (1:200, 
Jackson) for 1  hour at room temperature. Then, the slices were 
stained with DAPI (10 g/ml) for 10 min. The fluorescence images 
were obtained using a confocal microscope (Zeiss 880), and fluores-
cence intensity was analyzed by ImageJ software.
Blood biochemistry and blood routine examinations
Healthy Balb/c female mice at age 6 to 8 weeks were randomly 
divided into two treatment groups (n = 3). PBS and Gal-NP@siScr 
(1 mg of siRNA equiv./kg) were intravenously injected into mice via 
the tail vein (n = 3 per group). At prescribed time points after injec-
tion, blood was collected via eye socket bleeding. For blood bio-
chemistry examination, whole blood was centrifuged at 800g for 
5 min to collect serum for analysis. Standard blood chemistry 
parameters were analyzed using a kit from Wuhan Servicebio Tech-
nology Co. Ltd. on an automated chemistry analyzer (Chemray 240 
Rayto lnc.). Blood cell parameters were analyzed with an automated 
blood cell analyzer (BC-2800Vet-Mindray Inc.).
Novel object recognition
The NOR test was performed according to published methods (32). 
The experimental apparatus was a polyethylene white rectangular 
open field box (50 cm by 50 cm by 50 cm). Habituation took place 
by exposing the animal to the experimental apparatus for 10 min in 
the absence of objects on the day before training. During the train-
ing phase, mice were placed in the experimental apparatus in the 
presence of two identical objects (odorless wood cuboid or pyramid 
was used to prevent mice from climbing onto the object, avoid mice 
preference and sitting on it) and were allowed to explore the object 
for 10 min. After 24 hours, mice were placed again in the apparatus, 
where this time one of the objects was replaced by a novel one. Mice 
were allowed to explore for 10 min. DI and PI were used to assess 
NOR; this index accounts for differences in exploration time. DI 
and PI are calculated as the time spent exploring (total exploration 
of at least 30 s, sniffing, trying to move, and front paw pushing the 
objects were defined as exploring, but not the time spent near the 
objects without investigation, or passing by the objects). Data were 
collected using tracking software, and manual scoring was used to 
assess behaviors from the videos. DI was calculated as the time 
spent exploring the novel object minus the time spent exploring the 
familiar object, divided by the total exploration time. PI was calcu-
lated as the proportion of total time spent exploring new or old ob-
ject. [DI = Tnovel − Tfamiliar/(Tnovel + Tfamiliar), PI = Tnovel or Tfamiliar/
(Tnovel + Tfamiliar)]. All DI values fall between −1 and +1, and PI val-
ues fall between 0 and 1.
Nest construction
The nest construction experiment was adapted from published 
methods (29). Test mice were caged and housed one mouse per 
cage. A pad of paper, 1 cm thick, was available in the cage before the 
start of the test. On the first day of the test, three pieces of paper 
(5 cm by 5 cm, kitchen towel) were introduced inside the home cage 
to allow assessment of nest-building behavior. After 24 hours, the 
nest was photographed and scored as follows: 0 points, no paper 
towels at all; 1 point, paper towels scattered throughout the cage, 
but no obvious bite marks (indicating active nest construction); 
2 points, paper towels are concentrated in the cage, but no obvious 
bite marks; 3 points, the paper towel was concentrated on one side 
or one corner with some bite marks; 4 points, most of the paper 
towels were bitten and gathered together. The paper, which was 
shredded into small pieces or full of holes, was defined as bitten. All 
results were scored blindly.
Morris water maze
To evaluate spatial learning and memory, MWM was performed in 
accordance with standard protocols (52). The pool was divided into 
four quadrants (Fig. 4G), and on the wall of each quadrant, a differ-
ent symbol (pentagram, square, triangle, and circle) was affixed to 
provide extra-maze spatial cues. The water temperature was kept at 
22 ± 1°C, and highly dispersed food-grade titanium dioxide was 
added into water to aid animal tracking. All MWM experiments 
were carried out daily and, at the same time, in the afternoon. The 
experimental equipment was kept in a confined space without noise 
or strong light sources.
Mice were habituated to the room for 2 hours before the experi-
ment. Each mouse was trained to find a hidden platform for five 
consecutive days with four trials per day, with a 20- to 30-min inter-
trial interval. The mice were put into the water with their heads 
facing the wall of the pool, and the platform was allocated random-
ly to one of the four quadrants. The time the animals took to find 
the platform was recorded. In the training sessions, if the latency to 
find the platform exceeded 60 s, the animals were guided to the 
platform and kept there for 10 s. Mice were trained for 5 days to 
find the platform. Twenty-four hours after training, the platform 
was removed and the 60-s probe test commenced. Animals were 
placed into the water facing the quadrant, which was opposite the 
target quadrant. The time spent in the target quadrant and number 
of crossing the platform location was recorded as an indicator of 
spatial memory.
Statistical analysis
Results were analyzed by using GraphPad Prism software. Differ-
ences between two groups were assessed using unpaired t tests. For 
multiple comparisons, statistical significance was analyzed using 
one-way analysis of variance (ANOVA), followed by Fisher’s least 
significant difference post hoc test, which was used when compar-
ing all the conditions. Statistical differences in behavioral data were 
determined using two-way repeated-measures ANOVA. The level 
of statistical significance was set at P < 0.05. *P < 0.05 was consid-
ered significant, and **P < 0.01 ***P < 0.001 were considered highly 
significant. All data were expressed as mean ± SEM unless otherwise 
indicated.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/41/eabc7031/DC1
View/request a protocol for this paper from Bio-protocol.
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